<DOC>
	<DOC>NCT00704808</DOC>
	<brief_summary>The purpose of this surveillance is to collect more safety and efficacy data in "non-study" patients during concomitant and adjuvant temozolomide therapy.</brief_summary>
	<brief_title>Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must have newly diagnosed and operated glioblastoma multiforme with postoperative residual tumor &lt;=1.5 cm by magnetic resonance imaging (MRI). Age &gt;=18 years. Hemoglobin &gt;=10 g/dL. White blood cell count &gt;=1.5x10^9/L. Platelet count &gt;=100x10^9/L. Blood urea &lt;=1.5 x upper limit of normal values (ULN). Creatinine &lt;=1.5 x ULN. Bilirubin &lt;=1.5 x ULN. Aspartate aminotransferase &lt;=3 x ULN. Alanine aminotransferase &lt;=3 x ULN. Alkaline phosphatase &lt;=2 x ULN. Tumorspecific pretreatment. Contraindication against radiotherapy and/or chemotherapy. Malignomas other than basaliomas. Existing or planned pregnancy or lactation or inadequate contraception. Psychiatric disease. Simultaneous participation in another clinical trail or participation in another clinical trail in the last 30 days before recruitment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>